2. Search Result
Search Result
Results for "

MAA

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Fluorescent Dye

1

Inhibitory Antibodies

1

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99415
    Abelacimab

    MAA868

    		 Factor Xa Cardiovascular Disease
    Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .
    Abelacimab
  • HY-148875
    Py-MAA-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Cancer
    Py-MAA-Val-Cit-PAB-MMAE is a drug-Linker conjugates for ADC, which is composed of MMAE (HY-15162) and Py-MAA-Val-Cit-PAB linked. Py-MAA-Val-Cit-PAB-MMAE can be used to synthesize Zapadcine-3a, which targeting TRAILR2. Zapadcine-3a has broad-spectrum anti-tumor activity, and can specifically kill TRAILR2-positive tumors .
    Py-MAA-Val-Cit-PAB-MMAE
  • HY-N12931F
    Maackia amurensis Lectin (MAA/MAL II)-Biotinylated

    		Fluorescent Dye Others Cancer
    Maackia amurensis Lectin (MAA/MAL II)-Biotinylated is a plant lectin modified by biotin. Maackia amurensis Lectin (MAA/MAL II)-Biotinylated has the activity to recognize specific sugar structures, specifically the alpha-2, 3-linked sialic acid (HY-I0400). Maackia amurensis Lectin (MAA/MAL II)-Biotinylated has a very high affinity with avidin or streptavidin and this interaction can be used to fix it to solid surfaces or bind it to other molecules. Maackia amurensis Lectin (MAA/MAL II)-Biotinylated can be used to isolate and purify proteins or other molecules with specific sugar chain structures in affinity chromatography as well as for disease marker discovery and cancer research .
    Maackia amurensis Lectin (MAA/MAL II)-Biotinylated
  • HY-153236
    Py-MAA-Val-Cit-PAB-DX8951

    		Nucleoside Antimetabolite/Analog Others
    Py-MAA-Val-Cit-PAB-DX8951 is a purine toxin. Py-MAA-Val-Cit-PAB-DX8951 can be used as an intermediate in the synthesis of antibody-drug conjugates .
    Py-MAA-Val-Cit-PAB-DX8951
  • HY-RS08985
    NAA10 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    NAA10 Human Pre-designed siRNA Set A contains three designed siRNAs for NAA10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NAA10 Human Pre-designed siRNA Set A
    NAA10 Human Pre-designed siRNA Set A
  • HY-184073
    Mal-PEG8-CO-Ala-Ala-Asp-MAA

    		Biochemical Assay Reagents Cancer
    Mal-PEG8-CO-Ala-Ala-Asp-MAA is a linker. Mal-PEG8-CO-Ala-Ala-Asp-MAA can be used to synthesize QHL-1618 (HY-176772). QHL-1618 is a tumor microenvironment-activated conjugate. QHL-1618 inhibits tumor growth in various tumor models .
    Mal-PEG8-CO-Ala-Ala-Asp-MAA
  • HY-W017180
    2-(Bromomethyl)acrylic acid

    α-(Bromomethyl)acrylic acid; α-Methylated acrylamide; α-MAA

    		 Btk Cancer
    2-(Bromomethyl) acrylic acid is a Bruton's tyrosine kinase (BTK) inhibitor. 2-(Bromomethyl) acrylic acid forms a covalent bond with the cysteine 481 (Cys481) residue of BTK via a nucleophilic addition-elimination reaction, thereby inhibiting the downstream B-cell receptor signaling pathway. 2-(Bromomethyl) acrylic acid induces immunogenic cell death in BTK-expressing B-cell lymphoma cells by releasing damage-associated molecular patterns including extracellular ATP and HMGB1. 2-(Bromomethyl) acrylic acid exhibits cytotoxicity against BTK-expressing B-cell lymphoma cells, but shows low toxicity to BTK-negative cells. 2-(Bromomethyl) acrylic acid can be used in studies related to B-cell lymphoma .
    2-(Bromomethyl)acrylic acid
  • HY-181546
    Ibt-DOX

    		Btk PERK Syk HMG Family Cancer
    Ibt-DOX is a BTK inhibitor with an IC50 of 2.89 nM. Ibt-DOX is also a targeted covalent activated chemotherapeutic agent composed of the targeting ligand Ibrutinib (HY-10997), Doxorubicin (DOX) (HY-15142A), α-MAA (HY-W017180), and a linker (HY-Y0892). Ibt-DOX specifically binds to BTK and releases DOX, synergistically achieving BTK inhibition and chemotherapeutic killing, significantly enhancing toxicity against B-cell lymphoma cells and greatly reducing the toxic side effects of DOX on BTK-negative cells. Ibt-DOX can be used in lymphoma-related research .
    Ibt-DOX

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: